Brooke Wethington, PA
Physician Assistant · Foley, ALNPI 1427593680
Payments from drug & device makers
Across 160 payments — averaging $15.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$357
- Amarin Pharma, Inc.$212
- Novo Nordisk$206
- AbbVie$157
- Boehringer Ingelheim$142
- GSK$142
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,424100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 30 | $357 |
| Amarin Pharma, Inc. | 16 | $212 |
| Novo Nordisk | 10 | $206 |
| AbbVie | 12 | $157 |
| Boehringer Ingelheim | 6 | $142 |
| GSK | 14 | $142 |
| E.r. Squibb & Sons, L.L.C. | 8 | $124 |
| Pfizer | 5 | $92 |
| Amgen | 4 | $89 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $79 |
| Novartis | 5 | $77 |
| Lilly USA, LLC | 5 | $73 |
| Grifols USA, LLC | 4 | $69 |
| Bayer | 3 | $66 |
| Exact Sciences | 3 | $60 |
| Merck | 3 | $59 |
| AstraZeneca | 4 | $52 |
| Daiichi Sankyo Inc. | 3 | $51 |
| Mylan Specialty L.p. | 2 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Esperion Therapeutics, Inc. | 3 | $35 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Arbor Pharmaceuticals, Inc. | 2 | $26 |
| Dexcom, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Eisai Inc. | 1 | $22 |
| Medicure Pharma Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 2 | $16 |
| Insulet Corporation | 1 | $14 |
| Smith+Nephew | 1 | $13 |
How this compares
$2,432 in reported general payments places this provider in the 80th percentile of 846 physician assistant providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $136,644 |
| MounjaroTirzepatide | 66 | $93,355 |
| EliquisApixaban | 50 | $56,652 |
| TrulicityDulaglutide | 35 | $55,891 |
| JardianceEmpagliflozin | 27 | $27,453 |
| FarxigaDapagliflozin Propanediol | 19 | $16,492 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $5,773 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,740 |
| Levothyroxine Sodium | 187 | $2,668 |
| Duloxetine Hcl | 71 | $2,047 |
| Rosuvastatin Calcium | 148 | $1,976 |
| Omeprazole | 86 | $1,734 |
| Ezetimibe | 61 | $1,353 |
| Atorvastatin Calcium | 121 | $1,114 |
| Losartan Potassium | 113 | $1,109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $73 | $149,246101 claims |
| Novo NordiskOzempic | $206 | $136,644109 claims |
| PfizerEliquis | $92 | $56,65250 claims |
| Boehringer IngelheimJardiance | $142 | $27,45327 claims |
| AstraZenecaFarxiga | $52 | $16,49219 claims |
| GSKBreo Ellipta | $142 | $5,77313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 846 physician assistant providers in Alabama.
Other physician assistant in Foley
- Natalie GeorgeBirmingham$540K
- Lauren MillerAnniston$487K
- Valerie GoodwinBirmingham$33K
- Brianna BarryEnterprise$29K
- Ashley PeaceMobile$27K
- Andrea WombleHuntsville$22K
- Marlee BrunoDecatur$19K
- Mary TemplinBirmingham$19K
- Gregory SharpMobile$19K
- Elizabeth SimpsonMobile$18K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.